Adverum Biotechnologies Inc Key Opinion Leader Discussion of Additional Cohort 1 Data from the Phase 1 OPTIC Trial Transcript
So it's webcast today. So just need to make sure we're right on the time with 10:30 time slot.
Okay. Good morning, and welcome, everyone, to the Adverum KOL event. I'm Leone Patterson, the CEO of Adverum. And I know there's a lot going on AAO today, so I'm glad you could all make it here. I think we will make it interesting enough to -- with the specialists we have today that are going to be on our panel along with the additional data that we have presented yesterday that we would love to take you through.
We have about an hour, so I'll keep my opening remarks short and -- because we want to allow time for obviously our retinal specialists to provide their outlook on treating patients of wet AMD and also allow enough time for Q&A.
A copy of our slides can be found on our website at adverum.com. And also we will be making forward-looking statements today, which will be subject to risks and also uncertainties that may cause actual results to differ.
So starting with the agenda, which we think is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |